AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2026
Jan 21, 2026
30751_dirs_2026-01-21_35317f8d-5a20-4dd5-a1da-57b38f0cdea0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2026-01-16
Reporting Person: Iannone Robert (EVP, Global Head of R&D & CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-16 | Ordinary Shares | A | 11699 | $0.0 | Acquired | 84398 | Direct |
| 2026-01-16 | Ordinary Shares | F | 4140 | $171.16 | Disposed | 80258 | Direct |
Footnotes
F1: Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance
attained was certified.
F2: The Reporting Person acquired 71 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025.
F3: Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations.